drugset
drugset / Trial / NCT04502030

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

NCT04502030 ↗

Phase 3 Completed 247 enrolled Octapharma
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia

Timeline

Start
2020-10-05
Primary completion
2025-09-19
Completion
2025-09-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic — Intravenous

Indications

B cell deficiency B-cell chronic lymphocytic leukemia